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Patients with epilepsy (PwE) have an increased risk of active and lifetime depression. Two
in 10 patients experience depression. Lack of trained psychiatric staff in low- and middle-
income countries (LMIC) creates a need for screening tools that enable detection of depres-
sion in PwE. We describe the translation, validity and reliability assessment of the Patient
Health Questionnaire-9 (PHQ-9) as a screening tool for depression among PwE in Rwanda.
Method
PHQ-9 was translated to Kinyarwanda using translation-back translation and validated by a
discussion group. For validation, PwE of�15 years of age were administered the PHQ-9
and Hamilton Depression Rating Scale (HDRS) by trained psychiatry staff at Visit 1. A ran-
dom sample of 20% repeated PHQ-9 and HDRS after 14 days to assess temporal stability
and intra-rater reliability. Internal structure, reliability and external validity were assessed
using confirmatory factor analysis, reliability coefficients and HDRS-correlation, respec-
tively. Maximal Youden’s index was considered for cut-offs.
Results
Four hundred and thirty-four PwE, mean age 30.5 years (SD ±13.3), were included of whom
33.6%, 37.9%, 13.4%, and 15.1% had no, mild, moderate and severe depression, respec-
tively. PHQ-9 performed well on a one-factor model (unidimensional model), with factor
loadings of 0.63–0.86. Reliability coefficients above 0.80 indicated strong internal consis-
tency. Good temporal stability was observed (0.79 [95% CI: 0.68–0.87]). A strong correla-
tion (R = 0.66, p = 0.01) between PHQ-9 and HDRS summed scores demonstrated robust
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Conclusion
PHQ-9 validation in Kinyarwanda creates the capacity to screen PwE in Rwanda at scores
of�5 for mild or moderate and�7 for severe depression. The availability of validated tools
for screening and diagnosis for depression is a forward step for holistic care in a resource-
limited environment.
Introduction
Depression and epilepsy are each associated with a significant burden of disease globally, and
are known to occur together. In fact, depression is the most frequent psychiatric comorbidity
reported by patients with epilepsy (PwE). Compared with the general population, PwE have a
significantly increased risk of active and lifetime depression [1, 2]. Depression has been shown
to exacerbate adverse events associated with antiepileptic drugs, such as suicidal ideation; fur-
ther, patients with depression experience increased levels of stigma [1, 3–7]. Prevalence of
active depression in PwE ranged between 14.6% and 23.1% [2, 8, 9]. Up to 1/3 of PwE may
experience a major depressive episode in their lifetime [9].
Although depression has a key position in holistic care for PwEs, many healthcare profes-
sionals tend to focus attention predominantly on the medical aspects of epilepsy, often neglect-
ing the psychosocial burden of the disease [10]. Psychiatric comorbidities, therefore, remain
under-recognised and undertreated, especially in low- and middle-income countries (LMICs)
such as Rwanda [5, 11, 12]. Both diseases are subject to a large diagnosis and treatment gap,
and are considered to have a burdensome stigma. This is particularly concerning if the burden
of both epilepsy and depression are greatly underestimated or if the prevalence of epilepsy is
high. For instance, depressive disorders greatly impact disability in sub-Saharan Africa, and
are considered a leading cause of years lost due to disability [13]. In Rwanda, the prevalence of
epilepsy is up to 49 per 1,000 individuals [14], amongst the highest in Africa. Moreover, the
prevalence of depression in PwE is higher in Africa than in developed countries [15–19].
Central to addressing the gap in depression care in PwE in Africa is the ability to screen
patients living with or at risk of depression. A number of screening tools are available to enable
healthcare providers to identify depression among PwE, including the Patient Health Ques-
tionnaire-9 (PHQ-9).
The PHQ-9 is the nine-item depression module of the full PHQ, the patient-administered
version of the Primary Care Evaluation of Mental Disorders (PRIME-MD) screening tool,
which is administered by healthcare providers [20]. The PHQ-9 follows the diagnostic criteria
for depression of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV). It can be used as an algorithm to monitor and screen for major depressive disorder
(MDD) [20]. The PHQ-9 has been widely studied in developed countries, with optimal cut-off
scores to identify MDD varying from 8 to 11 points [21–24]. However, variations of cut-offs
have been reported considering the targeted population and setting.
Although developed and validated for diagnosing depression in primary care, the use of
PHQ-9 as a screening tool has also been validated in other clinical settings, among patients
with different ethnicities and in different countries [25–34]. Some studies reported the applica-
bility of PHQ-9 in sub-Saharan Africa, including Nigeria [35], Ethiopia [36–38], Kenya [39,
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40], Malawi [41], Cameroon [42], Uganda [43] and South Africa [44, 45], but none in Rwanda.
Psychometric properties of PHQ-9 have been described as a screening tool for depression, and
cut-offs of 5–10 were found to be optimal in general populations [35, 38, 42, 43], while cut-offs
of 8–9 were optimal in specific populations [36, 41]. Thus only a few countries in Africa have
reported the psychometric properties of PHQ-9 for targeted populations and conditions, and
how PHQ-9 performs in PwE has not been ascertained. In fact, a recent review revealed only
four studies reporting evidence of validity of PHQ-9 for screening for depression in PwE [46];
none were conducted in Africa.
Rwanda is a landlocked country in East Africa and home to 12.63 million inhabitants,
mean age 20y, of which less than 20% live in urban areas. A community-based health insur-
ance model provides cost coverage. Its healthcare system operates health centers, health posts,
dispensaries, district hospitals and reference hospitals. Access to neurologists is limited with
0.024 neurologists per 100,000 inhabitants. The CARAES Neuropsychiatric Hospital in Ndera
is a reference hospital for mental health, both psychiatry and neurology in- and outpatient
care. Of the 21,690 neurology outpatient consultations performed in 2018 at the center, epi-
lepsy accounted for 84.6%.
In the current study, the steps taken for the translation, and subsequent assessment of valid-
ity and reliability of PHQ-9 as a tool for screening for depression among PwE in Rwanda, are
described.
Methods
The study was conducted over a 4-month period at the Neuropsychiatric Hospital in Ndera,
just outside of Kigali, Rwanda. The study was approved by the Institutional Review Board of
the Rwanda National Health Research Committee and the National Ethics Committee. Writ-
ten informed consent was obtained from study participants before data collection. For patients
aged<18y, an additional assent form was signed by the caregiver.
Study participants
PwE with a clinically confirmed diagnosis by a neurologist and�15 years of age, attending the
neurology outpatient department of the Neuropsychiatric Hospital, were consecutively
enrolled in order of attendance when providing consent. Patients who had a concomitant clin-
ical diagnosis of depression, or reported signs and symptoms of depression, were included.
However, those with other psychiatric morbidities were excluded. Presence of co-morbid
depression or depressive symptoms as well as other psychiatric diseases was based on assess-
ment by the treating physician following clinical interview.
Procedure
At the first visit, trained medical nurses and healthcare providers administered the PHQ-9. On
the same day, the Hamilton Depression Rating Scale (HDRS), validated in Kinyarwanda for
diagnosis of depression, was also administered by trained psychiatry nurses, psychologists and
psychiatrists. Investigators administering HDRS were blinded throughout the study to the
results of PHQ-9 and vice versa. The Kinyarwanda version of the HDRS was used as the com-
parator/gold standard measure of symptom severity.
A randomly selected sample of 20% of all participants returned after 14 days for a follow-up
assessment, and completed the PHQ-9 and HDRS again, administered by the same investiga-
tor as on the first visit. This enabled evaluation of its temporal stability and intra-rater reliabil-
ity. All responses were collected through electronic data capturing and entered into an SQL
database.
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Sample size calculation
Sample size was estimated using both Gorsuch’s rule and sample sizes from Comrey and Lee.
Gorsuch’s rule requires a sample size of five times the number of questions assessed, a total of
36 in this study, resulting in minimal sample of 180 patients. Comrey and Lee consider a sam-
ple size >300 as good and >500 as very good. Based on recruitment feasibility at the center,
we aimed for a sample size of 400 patients.
Instruments
Translation and adaptation of PHQ-9. Coordinated by the Integration of HIV Care into
Mental Healthcare Services Technical Working Group, the questionnaire was translated from
English to Kinyarwanda in 2011. The team was supervised by the International Center for
HIV/AIDS Program (ICAP) of the University of Columbia (USA), the Rwanda Biomedical
Center/Mental Health division, and the University of Rwanda. A structured approach using a
back-translation technique combined with bilingual technique was used [47]. A discussion
group, including 10 doctors and psychologists with experience in depression, achieved consen-
sus on the wording of the translated PHQ-9, addressing five major dimensions for cross-cul-
tural equivalence defined by Flaherty [48].
HDRS. The HDRS has been used for assessing severity of depression, changes in severity
over time, and treatment efficacy, with good overall levels of internal consistency, inter-rater
and test–retest reliability [49–51]. The HDRS was used as our gold standard anchor to evaluate
the screening ability of the Rwandan adapted PHQ-9. The HDRS was translated at the CAR-
AES Neuropsychiatric Hospital in Ndera, Rwanda, in 2013 and found to be associated with
reliable internal consistency (Cronbach’s alpha = 0.96) [18].
In a previous analysis, we determined a single HDRS cut-off point for diagnosis of depres-
sion in a Rwandan population. This showed that a score of 17 was the optimal cut-off point to
diagnose an MDD, based on expert diagnostic assessment. Since we did not establish cut-off
points based on intervals of depression severity, for the current study we compared the PHQ-9
diagnostic ability against international standard intervals suggested in the literature (Table 1)
[52], in addition to the single Rwandan cut-off defined in our previous study.
Data analysis
Sociodemographic data are presented as means with standard deviations, medians with the
interquartile range, or absolute and relative frequencies. All analyses were conducted with R
Language for Statistical Computing v. 3.5 using the lavaan and receiver operating characteristic
(ROC) packages (R foundation, Vienna) [53]. Given a small number of patients aged <18, we
performed a post-hoc sensitivity analysis excluding those.
Table 1. HDRS Depression screening cut-off points.
HDRS interval Depression level [52]




HDRS cut-off Rwanda Moderate and severe depression in Rwandan population
>17 Moderate and severe depression
Abbreviation: HDRS, Hamilton Depression Rating Scale.
https://doi.org/10.1371/journal.pone.0234095.t001
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Evidence of reliability. As a first step in determining the reliability of the translated
PHQ-9, its internal consistency was evaluated. This can be assessed by several coefficients,
each with its strengths and limitations [54, 55]. For this study, we report the Cronbach’s alpha
and Composite Reliability (CR), with values above 0.70 considered adequate.
Temporal stability was first assessed by calculating the intra-class correlation (ICC) between
the scores of the PHQ-9 collected at two time points separated by 14 days. ICC values>0.8 are
considered good and values >0.9 are exceptional [56].
Evidence of validity based on internal structure. To test the internal structure of the
PHQ-9, network analysis and confirmatory factor analysis (CFA) was conducted.
For network analysis, graphs of undirected weighted networks were constructed based on a
polychoric correlation matrix of PHQ-9 items. Partial correlation coefficients were estimated
through nodewise multiple regression, with graphical least absolute shrinkage and selection
operator regularisation, or GLASSO [57]. Penalised model selection was made based on
extended Bayesian information criteria (EBIC) [58]. Those pairwise partial correlations were
depicted as edges connecting nodes. Node size varied according to the mean score for each
item. We performed a community structure analysis to identify underlying clusters of items.
Community structure analyses are applied to complex networks in which groups of variables
are densely interconnected among each other, but sparsely connected to the overall network.
The random walks method was incorporated into the Walktrap algorithm, which is suited for
weighted networks [59]. With random starts, a limited (in general, three or four) number of
steps or “walks” were performed between nodes in such a way that they became “trapped” in
high-density subgroups. All analyses were conducted with the R language for Statistical Com-
puting, through the qgraph and igraph packages.
Confirmatory factor analysis was used to determine whether the scores obtained from the
nine items of the questionnaire refer to the single construct of depression. Such a single factor,
or unidimensional model for PHQ-9, has been reported by others for different populations
[37, 60]. The weighted least square means and variance adjusted estimator (WLSMV) was
used to test the adequacy of the model. The relationship between each item and depression
was determined by its factor loading (values above 0.50 deemed acceptable). Model adjust-
ment, or how well the model fits the data, was evaluated using several goodness-of-fit indices
and overall model theoretical interpretation. The fit indices, and the generally accepted refer-
ence levels for a good fit (in parentheses), were the following: Chi-square (χ2 and p-value),
Root Mean Square Error of Approximation (RMSEA,�0.05), Tucker–Lewis index (TLI,
>0.95), Comparative Fit Index (CFI,�0.95) and Average Variance Extracted (AVE, >0.50)
[61–63].
Evidence of validity based on relationship with other constructs. The validity of the
translated PHQ-9 was determined using two methods. For both methods, we used the HDRS
as the reference for external validity. First, we evaluated concurrent validity by correlating the
scores from PHQ-9 that were associated with the scores of the HDRS. We hypothesised that
the PHQ-9 score would positively and strongly predict the HDRS score (R >0.60).
For the second form of external validity, we evaluated the ability of PHQ-9 to identify
patients with depressive disorder as defined by the HDRS. We compared the PHQ-9 with two
cut-offs defined by the HDRS. Firstly, we evaluated the PHQ-9 parameters to identify a depres-
sive disorder according to the international standards defined as Absence (HDRS <8), Mild
(HDRS�8), Moderate (HDRS�17) and Severe (HDRS�24) (Table 1). Secondly, we specified
the ability of PHQ-9 to identify moderate to severe depression as defined by the Rwandan cut-
off for the HDRS, defined as scores�17. We evaluated the screening ability by measuring the
sensitivity, specificity and positive and negative predicted values. ROC curves were subse-
quently generated and the area under the ROC curve (AUROC) was calculated. Using this
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approach, the optimal cut-off point for the PHQ-9 as a screening tool for the levels of depres-
sion as anchored by the HDRS was determined, using both the international cut-offs and the
Rwandan cut-off for moderate to severe depression (Table 1). To establish the cut-off, You-
den’s index was employed to maximise sensitivity and specificity in detecting patients with
moderate to severe depression. As age and level of education may influence PHQ-9 cut-offs,
we evaluated the ROC and cut-offs for age groups of<30 years and�30 years of age, and by
level of education (no schooling/primary schooling and secondary/higher education).
Results
Study participants
Four hundred and thirty-four patients participated in the study. Only 2.1% were younger than
18 years of age (Table 2). Up to two-thirds of patients were unmarried. Most participants were
employed (59.2%), and more than half had completed secondary education (50.7%). The
Table 2. Sociodemographic and clinical characteristics of participants.
Patients (N = 434)
Age (years), mean ± SD 30.5 ± 13.3
Male, n (%) 259 (59.7)
Employed, n (%) 257 (59.2)
Education level, n (%)
No schooling 29 (6.7)
Primary 185 (42.6)
Secondary 171 (39.4)
Higher education 49 (11.3)





Not reported (<18 years of age) 9 (2.1)
Age at epilepsy onset (years), mean ± SD 20.8 (13.3)










PHQ-9, Mean (SD) 5.8 (5.4)
Abbreviations: HDRS, Hamilton Depression Rating Scale; PHQ-9, Patient Health Questionnaire-9; SD, standard
deviation.
�More than one type of seizure can be present in one patient; because of diagnostic limitations, focal to general
seizures were considered as possibly generalised.
https://doi.org/10.1371/journal.pone.0234095.t002
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average age at epilepsy onset was approximately 21 years. Based on the HDRS, 66.4% of
patients were diagnosed as having depression.
Rwandan PHQ-9 characterisation
Overall PHQ-9 score was 5.8 (SD 5.4). All items had a varied distribution of Likert options
endorsed (Fig 1A), with higher frequencies for options 3 and 4. Items 2, 4 and 6 had the highest
averages among all PHQ-9 items (Fig 1B). Associations between items showed that all items
correlated with each other (all correlations had R>0.50). When adjusting for all the correla-
tions (partial correlations) in a network model, items 1 and 5 showed a negative correlation.
All items clustered within one community, as expected. Items 1, 3 and 7 had the highest mea-
sure of betweenness and expected influence, suggesting that these items are relevant depres-
sion symptoms in the behaviour of other depressive symptoms measured using the PHQ-9.
Internal structure and reliability
Parallel analysis supported the unidimensional structure of the Rwandan version of the PHQ-
9. The one-factor model (unidimensional model) performed well using PHQ-9, and displayed
a good fit for the data (Table 3). All nine PHQ-9 items were loaded onto one single factor, with
factor loadings for all items in the range 0.63–0.86 (Fig 2). For the reliability of the PHQ-9
items, values above 0.80 were obtained for both reliability coefficients, indicating strong inter-
nal consistency (Table 3). Analysis of stability over time in the PHQ-9 assessment through the
ICC showed good temporal stability with a score of 0.79 (95% CI: 0.68–0.87) (Table 3).
A B
100
Response ■ Birenze igice cy’umunsi ■ Hafi ya buri muns
■ Nta na rimwe ■ Rimwe na rimwe















































Fig 1. Likert responses distribution (A) and correlation pattern between items (B) of the Rwandan version of the PHQ-9. The size of the nodes (circles) represents the
average response in the Likert scale for each item. The thickness of the lines (edges) represents the partial correlation between items. Nta na rimwe = not at all, never;
Rimwe na rimwe = several days, sometimes; Birenze igice cy’umunsi = more than half the days; Hafi ya buri munsi = nearly every day.
https://doi.org/10.1371/journal.pone.0234095.g001
PLOS ONE Validated cut-offs for PHQ-9: a screening tool for depression in patients with epilepsy in Rwanda
PLOS ONE | https://doi.org/10.1371/journal.pone.0234095 June 12, 2020 7 / 16
Correlation and diagnostics indicators with HDRS
A strong, positive correlation (R = 0.66, p = 0.01) was observed between PHQ-9 and HDRS
summed scores, indicating robust external validity and high agreement between both tools. In
terms of the diagnostic validity of PHQ-9 relative to HDRS, the PHQ-9 showed good accuracy
(area under the curve [AUC] >0.80) in discriminating between participants who did not have
depression and those with mild or moderate and severe depression (Table 4).
Interestingly, the optimal cut-off point for the PHQ-9 was the same for the HDRS groups of
mild depression and moderate depression (5 or more). The cut-off for identifying severe
depression, as measured by the HDRS was 7 or more (Table 4). The cut-off for the Rwandan
version of the HDRS moderate-severe classification was also 7 or more. Detailed values are
provided in S1 Table (see Supporting Information). A post-hoc sensitivity analysis, excluding
PwE<18y (2.1%), did not affect cut-offs nor validity.
Table 3. Reliability measures, model parameters and goodness-of-fit indicators of the CFA model.
PHQ-9
CFA fit indicators
X2 (Degrees of Freedom) 61.89 (36)
RMSEA (95% CI) 0.06 (0.04–0.08)
Tucker–Lewis Index 0.99
Comparative Fit Index 0.99
Reliability indicators
Cronbach’s alpha (95% CI) 0.87 (0.85–0.89)
Composite reliability 0.97
Temporal stability (95% CI) 0.79 (0.68–0.87)
Model parameters
Factor loadings range 0.63–0.86
Average variance extracted 0.63
Abbreviations: CFA, confirmatory factor analysis; CI, confidence interval
RMSEA, Root Mean Square Error of Approximation.
https://doi.org/10.1371/journal.pone.0234095.t003
0.76 0.74 0.69 0.76 0.63 0.790.79 0.71
0.31
0.86
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
PHQ9
Fig 2. Confirmatory factor analysis models for PHQ-9.
https://doi.org/10.1371/journal.pone.0234095.g002
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Subgroup analysis by age and education
Subgroup analyses by age and schooling, factors possibly influencing PHQ-9 cut-offs, showed
only small differences between groups in optimal cut-offs (Table 5), demonstrating little influ-
ence of these factors.
Discussion
The study was conducted to assess the reliability and validity of the PHQ-9 as a screening tool
for depression in a population of Rwandan patients with epilepsy. This study is unique because
it addresses the gap of evidence with respect to the psychometric properties of the PHQ-9 and
confirms its clinical usefulness in Rwandan PwE. The ROC analysis showed that PHQ-9
thresholds of 5 or more and 7 or more offered the optimal discriminatory power in detecting
MDD severity levels (mild, moderate or severe) with acceptable sensitivity, specificity and area
under the ROC curve. Overall, results indicated that the tool in Kinyarwanda displayed good
psychometric properties in this specific population.
The internal structure of the translated PHQ-9 was consistent with a single-factor model, or
unidimensional model, similar to that reported in other sub-Saharan countries and LMICs.
The observation that all nine items of the questionnaire load onto a single factor is an indica-
tion that the PHQ-9 is measuring a coherent, unitary concept of MDD based on the DSM-IV
criteria [33]. This single-factor model has also been reported in other studies conducted in
Table 4. Receiver operating characteristic curves of the PHQ-9 scores in relation to HDRS categories: Mild, moderate, severe.
Depression severity Optimal cut-off Sensitivity Specificity PPV NPV AUC
Mild (HDRS >7) >4 72.4 69.6 79.1 61.2 0.80 (0.74;0.86)
Moderate (HDRS >16) >4 88.8 59.1 50.6 91.8 0.84 (0.80;0.90)
Severe (HDRS >23) >6 93.7 65.3 32.4 98.3 0.87 (0.83;0.93)
Rwandan version (HDRS > 17) >6 84.1 75.1 58.2 92.0 0.86 (0.82;0.90)
https://doi.org/10.1371/journal.pone.0234095.t004
Table 5. Subgroup analysis of optimal cut-offs by age and level of education.
Depression severity Optimal cut-off Sensitivity Specificity PPV NPV AUC
Less than 30 years of age
Mild (HDRS >7) >4 64.9 71.4 77.8 56.9 0.78 (0.70;0.85)
Moderate (HDRS >16) >6 70.8 77.7 57.6 86.1 0.79 (0.71;0.87)
Severe (HDRS >23) >6 91.7 72.7 37.3 98.0 0.89 (0.83;0.95)
Above 30 years of age
Mild (HDRS >7) >4 75.4 0.68 79.3 0.63 0.80 (0.73;0.86)
Moderate (HDRS >16) >4 94.2 60.9 56.9 95.1 0.88 (0.82;0.92)
Severe (HDRS >23) >7 91.2 73.8 41.9 97.6 0.88 (0.82;0.93)
No education/ Primary education level
Mild (HDRS >7) >5 64.4 86.5 89.7 57.1 0.81
Moderate (HDRS >16) >6 78.8 74.8 59.1 88.4 0.83 (0.77;0.89)
Severe (HDRS >23) >7 90.6 74.6 39.2 97.8 0.86 (0.80;0.92)
Secondary or higher education level
Mild (HDRS >7) >4 74.6 69.0 77.1 65.9 0.80 (0.74;0.86)
Moderate (HDRS >16) >5 88.2 68.1 57.1 92.3 0.85 (0.80;0.90)
Severe (HDRS >23) >8 80.6 79.3 40.3 95.9 0.88 (0.83;0.93)
Abbreviations: AUC, area under the curve; HDRS, Hamilton Depression Rating Scale; NPV, negative predictive value; PPV, positive predictive value.
https://doi.org/10.1371/journal.pone.0234095.t005
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different populations [37, 39, 40, 42, 44], supporting the cultural consistency of this measure-
ment. However, this is the first time that this evaluation has been conducted in sub-Saharan
Africa and specifically on a population with epilepsy [33, 37, 60]. All goodness-of-fit indices
displayed values for a good fit and did not indicate issues with model identification and fitness.
The translated PHQ-9 was reliable, showing a high degree of internal consistency and tem-
poral stability. Values for all reliability coefficients were >0.80. While results for both tests
demonstrated good temporal stability, in the sample that was retested after two weeks, there
was more variability in the scores obtained at the two time points when the PHQ-9 was admin-
istered. The results were similar to other studies conducted in sub-Saharan Africa [35, 38, 42,
43]. In regard to validity, patients’ scores on the PHQ-9 correlated strongly with their scores
from the HDRS. The positive correlation confirmed the instrument’s ability to discriminate
levels of MDD in comparison with HDRS scores. Similar results were consistently reported in
the literature with diverse populations [64] but this is the first study reporting this validity in
patients with epilepsy in sub-Saharan Africa.
Our proposed cut-offs are lower than the score of 10 typically suggested as the cut-off point
for depression in a general population in developed countries [65]. However, studies in LMICs
in different settings and populations have reported cut-offs for any or mild depression of 5 and
severe depression of 10 in Nigerian students and in a Malaysian primary care setting [34, 35,
38, 42, 43].
Cut-offs for the PHQ-9 thus vary across populations [22], differing in clinical setting, con-
comitant disease and culture, and require population specific values rather than inflexibly
adhering to a single cut-off point [20]. Studies with targeted specific patient populations rec-
ommend highly variable cut-offs, ranging from 6–8 in chronically ill older patients in the
Netherlands [66] to 15 in white female psychiatric in-patients [67]. Other studies have reported
values in the range 8–12 in targeted populations including traumatic brain injury [68], HIV
[39, 45], cancer [40] and diabetes [69].
Our cut-off of�5 for moderate and�7 for severe depression in PwE is amongst the lowest
of targeted populations and lower compared to cut-offs for PwE of 9 [8] in Canada and 10–15
in the United States [9]. To explain heterogeneity between cut-offs, a meta-analysis was con-
ducted to explore possible factors, which found that blind application of a diagnostic gold stan-
dard was a predictive source of heterogeneity [22]. In our study, the administrator of the
diagnostic gold standard was blinded to the PHQ-9 results. We also explored possible sub-
group differences in our own sample, as education level and age have been suggested to influ-
ence PHQ-9 [70]. In our sub-group analysis, no clinically relevant differences for PHQ-9 cut-
offs between age groups and educational levels were observed.
Underreporting of depressive symptoms is another probable contributor to lower cut-offs.
Firstly, the presence of disease specific symptoms that are difficult to disentangle from somatic
symptoms of depression, may lead to underreporting of depressive symptoms by patients.
Indeed, improved clinical utility of the Beck Depression Inventory has been observed in HIV
patients when somatic items were removed from the questionnaire [70]. Concerning our data,
epilepsy is often associated with disease related symptoms or treatment side effects such as
fatigue and somnolence, poor concentration or appetite and weight changes, which are all the
subject of questions on the PHQ-9. The impact of epilepsy specific symptoms on the perfor-
mance of depression scales has to our knowledge not been studied and requires more research.
Second, differences between populations and cultures need to be considered, such as enacted
and self-stigma, which negatively affect help- and care-seeking patterns [71]. Underreporting
of depressive symptoms due to social and self-stigma has been documented in war veterans,
who reported depressive symptoms up to 4 times more frequently during an anonymous
paper questionnaire compared to normal routine healthcare visits [72]. A study from India
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confirmed a relationship between self-stigma and PHQ-9 scores among college students [73].
In Turkish patients, a stigma score combined for enacted and self-stigma, accounted for 26.2%
of the variance in the BDI score [74]. In Rwanda, epilepsy-related enacted stigma is significant
as nearly two-thirds of the general population would exclude PwE from school, work and
social gatherings [14]. Anticipation of a diagnosis of a mental health disorder such as depres-
sion, may thus impact PHQ-9 scoring by PwE experiencing any form of stigma. Clearly, the
effects of social and self-stigma on PHQ-9 scoring in PwE has not yet clearly been elucidated.
We recommend future research addresses factors that influence the variability of the raw
scores and cut-offs, including disease related somatic symptoms and stigma as they probably
account for the variability observed in recommended cut-offs.
One limitation of this study is that only patients with epilepsy�15 years of age were
included. Therefore, cut-offs may not be applicable to paediatric PwE, or to the general Rwan-
dan population. We included too few patients of<18 years of age to perform subgroup analy-
sis on this specific subgroup. Further studies should replicate the scales in other samples and
other cultures to confirm the psychometric properties in adolescents.
Another limitation is the comparator chosen for confirmation of depression [46]. The gold
standard for diagnosis of depression is the structured interview. In this study, we opted for the
HDRS as a diagnostic reference because it has already been validated in Rwanda with estab-
lished cut-offs for depression diagnosis. Although HDRS is not the most common method
used as an anchor for accuracy testing, HDRS specific cut-offs and ranges have been previously
validated in relation to a clinical interview and have been extensively reported as an accurate
measure for depression [28, 52, 75]. We selected HDRS as an anchor because its use can be
scaled in Rwanda to medical professionals working in resource-limited environments. When
there is limited availability of trained neurological or psychiatric medical staff to conduct a
structured interview for diagnosis of depression, psychometric tools are used to support
patient care.
For PwE in Rwanda, PHQ-9 and HDRS tools provide screening and diagnostic capabilities,
respectively, and will play a role in closing the diagnosis and treatment gap. The decision of
whether to screen for moderate/severe or severe depression only using PHQ-9 cut-offs of�5
and�7, respectively, will require careful consideration in each healthcare setting (healthpost,
healthcare center, district hospital) as screening for and diagnosis of depression will increase
the burden on mental healthcare.
Conclusion
Considering that depressive disorder is a major cause of comorbidity in epilepsy, this cross-
cultural validation further develops the capacity to screen for, measure, and treat depressive
disorders in patients with epilepsy in Rwanda. Given that a limited number of studies have val-
idated the use of the PHQ-9 in sub-Saharan Africa, our results allow more evidence-based clin-
ical practices. Cut-off scores of 5 and 7 or more for moderate and severe depression were
established. In essence, the availability of validated tools for screening and diagnosis for
depression in patients with epilepsy in Rwanda is an important step forward in their holistic
care in a resource-limited ecosystem.
Supporting information
S1 Table. PHQ-9 screening parameters for mild, moderate and severe depressive disorder
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Questionnaire-9; NPV, negative predictive value; PPV, positive predictive value; Sens,
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ple with epilepsy in Togo and Benin (West Africa) I. Anxiety and depression measured using Goldberg’s
scale. Epilepsy Behav. 2004; 5(5):722–7. https://doi.org/10.1016/j.yebeh.2004.07.001 PMID:
15380125
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